Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACH301: TYRA-300 in Children With Achondroplasia
NCT06842355Phase 2Recruiting
- Sponsor
- Tyra Biosciences
- Start
- Mar 2025
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of dabogratinib in achondroplasia (ACH), sponsored by Tyra Biosciences. Started Mar 2025; status: recruiting.
02
Drugs
dabogratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT06842355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842355.